Status:
COMPLETED
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
Lead Sponsor:
Avexa
Conditions:
HIV Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
Detailed Description
An ongoing study (AVX-201) is examining the safety and efficacy of apricitabine compared to 3TC in HIV patients who are failing therapy containing 3TC and have the presence of the M184V mutation in re...
Eligibility Criteria
Inclusion
- Completed AVX-201 protocol, Plasma HIV RNA \<5000 copies/ml, CD4 cells \>50
Exclusion
- Pregnant or breastfeeding females, withdrawal from AVX-201
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00367952
Start Date
August 1 2006
End Date
January 1 2010
Last Update
June 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Avexa (co-ordinating sites in Australia and Argentina)
Melbourne, Victoria, Australia, 3121